Article Text

AB0812-PC Clinical and epidemiological characteristics of women with breast cancer and aromatase inhibitors treatment who presented hip fracture between 2008-2010
  1. M. Pacin-Cebral1,
  2. L. López-Silva2,
  3. J. Miguel-Carrera3,
  4. S. Varela-Ferreiro4,
  5. C. Garcia-Porrua5
  1. 1Centro de Salud Islas Canarias
  2. 2Centro de Salud Milagrosa
  3. 3Centro de Salud Foz
  4. 4Oncology
  5. 5Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain


Background The main source of estrogen is produced in peripheral tissues in post-menopausal women. Due to this, lowering estrogen production at peripheral tissues with aromatase inhibitors might be an additional risk factor for osteoporosis and hip fracture.

Objectives Our aim was to analyzethe clinical and epidemiological characteristics of women who had a hip fracture and had been diagnosed as having breast cancer and treated with IA

Methods We conducted a retrospective study of the case records of all adults women diagnosed with hip fracture and IA treatment for breast cancer from January 2008 through December 2010. The Hospital Universitario Lucus Augusti is the only referral center for our population. Statistical analyses were performed using SPSS.

Results Thirteen women who had suffered breast cancer and IA treatment presented hip fracture during the period 2008-2010. From all hip fractures found, 7 were trochanteric, 3 subtrochanteric and 3 had occurred in femoral neck. The median age at the time of fracture was 83 years. All fractures require hospitalization and surgery. The median age at the time of breast cancer diagnosis was 72 years. All patients were treated with third-generation IA and none had been previously diagnosed as having osteoporosis. Five patients (38.4%) received anti-osteoporotic treatment after hip fracture.

Conclusions Hip fractures occur in those patients with breast cancer and treatment with IA when they have diagnosed in an elderly age (median age 72). In these patients, a better physician awareness looking for risk factor for osteoporosis, especially in elderly people could decrease the number of hip fractures. Treatment after hip fracture should be required.


  • Salgado BA, Zivian MT. Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Research and Treatment, 2006; 100: abstract 3131

  • Miguel-Carrera J, Varela-Prado ME, Bravo-Perez M, Garcia-Porrua C. Características epidemiológicas de los pacientes en tratamiento antiosteoporotico del Centro de Salud de Sarria (Lugo). Cadernos de Atencion Primaria 2011; 18:85-9

  • Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. European Guidance for Diagnosis and Management of Osteoporosis in Postmenopausal women. Osteoporosis Int. 2008; 19:399-428

  • Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, Mc Closkey EV, Reid DM, Selby P, Wilkins M; National Osteoporosis Guideline Group. Guidelines for diagnosis and management of osteoporosis in postmenopausal women and men from the 50 years in the UK. Maturitas 2009; 62:105-8

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.